Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas
OBJECTIVES:
- To investigate whether the expression of a subset of proteins (by
immunohistochemistry), known to be involved in the Pax3, Pax7, and Patched-1
neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar
and embryonal rhabdomyosarcomas.
OUTLINE: Iimmunohistochemistry is performed for each candidate target (Pax3, Pax7, and
Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue
microarray analysis.
Observational
N/A
Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma
No
Charles Keller, MD
Principal Investigator
Oregon Health and Science University
United States: Federal Government
CDR0000738499
NCT01668095
August 2012
Name | Location |
---|